Northland Capmk Issues Negative Estimate for HRTX Earnings

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Northland Capmk reduced their Q4 2024 EPS estimates for shares of Heron Therapeutics in a research report issued to clients and investors on Tuesday, November 12th. Northland Capmk analyst C. Byrnes now anticipates that the biotechnology company will post earnings per share of ($0.03) for the quarter, down from their previous estimate of ($0.02). The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.08) per share.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The business had revenue of $32.81 million for the quarter, compared to the consensus estimate of $36.40 million. During the same period in the prior year, the business posted ($0.17) EPS.

Other equities research analysts have also issued reports about the company. StockNews.com upgraded Heron Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday. Needham & Company LLC reduced their price objective on shares of Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Wednesday.

Heron Therapeutics Trading Down 4.0 %

Heron Therapeutics stock opened at $1.19 on Friday. The firm has a market cap of $181.00 million, a P/E ratio of -6.61 and a beta of 1.81. Heron Therapeutics has a 1-year low of $0.81 and a 1-year high of $3.93. The firm has a 50-day moving average of $1.82 and a 200-day moving average of $2.51.

Institutional Investors Weigh In On Heron Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Marshall Wace LLP boosted its stake in shares of Heron Therapeutics by 256.2% in the 2nd quarter. Marshall Wace LLP now owns 1,761,051 shares of the biotechnology company’s stock worth $6,164,000 after buying an additional 1,266,697 shares during the last quarter. Clearline Capital LP boosted its stake in Heron Therapeutics by 48.9% in the 3rd quarter. Clearline Capital LP now owns 2,226,512 shares of the biotechnology company’s stock worth $4,431,000 after purchasing an additional 731,246 shares during the period. AQR Capital Management LLC increased its holdings in Heron Therapeutics by 1,460.9% in the 2nd quarter. AQR Capital Management LLC now owns 607,135 shares of the biotechnology company’s stock valued at $2,125,000 after acquiring an additional 568,238 shares during the last quarter. Congress Park Capital LLC lifted its position in shares of Heron Therapeutics by 25.3% in the third quarter. Congress Park Capital LLC now owns 1,978,078 shares of the biotechnology company’s stock worth $3,936,000 after buying an additional 399,577 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its position in shares of Heron Therapeutics by 369.0% during the 2nd quarter. Squarepoint Ops LLC now owns 363,700 shares of the biotechnology company’s stock valued at $1,273,000 after acquiring an additional 286,160 shares during the last quarter. 80.01% of the stock is owned by hedge funds and other institutional investors.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.